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Abstract  The aim of this study is to explore the advantages of using human 
immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) in cDNA synthesis. 
Recombinant HIV-1 group M (HIV-1 M) RT and HIV-1 group O (HIV-1 O) RT were 
produced in an Escherichia coli expression system. In the incorporation of dTTP into 
poly(rA)-p(dT)15 (T/P), the Km values for dTTP of HIV-1 M RT and HIV-1 O RT were 
8 and 12% of that of Moloney murine leukemia virus (MMLV) RT, respectively, and 
the Km values for T/P were 25 and 23% of that of MMLV RT, respectively. Compared 
with MMLV RT, HIV-1 M RT and HIV-1 O RT were less susceptible to formamide, 
which is frequently used for cDNA synthesis with a G+C-rich RNA to improve 
specificity. The high substrate affinity and low susceptibility to formamide of HIV-1 RT 
might be advantageous for its use in cDNA synthesis.  
 






Reverse transcriptase (RT) is the enzyme responsible for viral genome replication. 
Moloney murine leukemia virus (MMLV) RT and Avian myeloblastosis virus (AMV) 
RT are widely used in cDNA synthesis. MMLV RT is a 75-kDa monomer comprising 
the fingers, palm, thumb, and connection subdomains and the RNase H domain [1–3]. 
AMV RT is a heterodimer consisting of a 63-kDa  subunit and a 95-kDa  subunit. 
Human immunodeficiency virus type 1 (HIV-1) RT is widely used as a tool in the 
development of inhibitors for the treatment of HIV-1 infection. It is a heterodimer 
consisting of a 51-kDa subunit (p51) and 66-kDa subunit (p66). p66 comprises the same 
five domains as MMLV RT, and p51 comprises the fingers, palm, thumb, and 
connection subdomains but lacks the RNase H domain [4–6]. HIV-1 RT exists as a 
heterodimer as well as a homodimer, and the dissociation constants (Kd) of p51 and p66, 
p66 and p66, and p51 and p51 were reported to be 0.31, 4.2, and 230 M, respectively 
[7]. HIV-1 is classified into four phylogenetic major groups: M (main), O (outlier), N 
(non-M/non-O), and P. Group M infection is spread all over the world. Group O 
infection is restricted to Cameroon and neighboring countries in West Central Africa [8]. 
The amino acid sequence homology between HIV-1 group M (HIV-1 M) RT and HIV-1 
group O (HIV-1 O) RT is 79% [8]. 
It is well known that the fidelity of HIV-1 RT is lower than those of MMLV RT and 
AMV RT [9]. Concerning this, Barrioluengo et al. reported that two single mutations 
(Lys65→Arg and Arg78→Ala) and one double mutation (Lys65→Arg/Val75→Ile) 
increase the fidelity of HIV-1 O RT to the same level as MMLV RT [9]. In addition, 
Álvarez et al. reported that HIV-1 O RT is more thermostable than MMLV RT [10]. 
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These results indicate that the HIV-1 O RT variants K65R, R78A, and K65R/V75I have 
the same fidelity as, and higher stability than MMLV RT. 
Low fidelity of RT is problematic for cloning of cDNA. However, extremely high 
fidelity is not required for detection of a target RNA in RT-PCR and RNA-specific 
amplification assays. RNA-specific amplification is an isothermal reaction (41-43 ºC) 
that is widely used in clinical diagnosis [11–14], in which RT synthesizes 
promoter-bearing double-stranded DNA with the help of its RNase H activity, and RNA 
polymerase continues in vitro transcription to produce copies of RNA fragments that are 
subsequently recycled as RNA templates for synthesis of promoter-bearing 
double-stranded DNA. To increase the sensitivity and rapidness, the reaction is carried 
out in the presence of deoxy-inosine triphosphate (dITP) and dimethyl sulfoxide 
(DMSO). The use of dITP surely decreases the fidelity of RT.  
In this study, we made enzymatic characterization of HIV-1 RT. The results have 
shown that HIV-1 RT has high substrate affinity and low susceptibility to formamide. 
These characteristics might be advantageous for using HIV-1 RT in cDNA synthesis.   
  
 




p(dT)15 was purchased from Life Technologies Japan Ltd. (Tokyo, Japan). 
[methyl-
3
H]dTTP (1.52 TBq/mmol) and poly(rA) were from GE Healthcare 




[15] using Protein Assay CBB Solution (Nacalai Tesque, Kyoto, Japan) with 
bovine serum albumin (Nacalai Tesque) as standard. Standard RNA, an RNA of 
1014-nucleotides corresponding to DNA sequence 8353–9366 of the cesA gene of 





The 2,002-bp DNA fragment encoding MMLV RT was amplified from the pUC19 
plasmid that contains the complete MMLV gene (8,332 bp) (GenBank accession no. 
J02255) [14], using the primers MRF and MRHISB. The 1,340-bp DNA fragment 
encoding HIV-1 M RT p51 gene was amplified using HIVRTM-HISF and 
HIVRTMp51-B, and the 1,706-bp DNA fragment encoding HIV-1 M RT p66 was 
amplified using HIVRTM-F and HIVRTMp66-B, both from the artificially synthesized 
HIV-1 M RT gene (Fig. S1A). The 1,340-bp DNA fragment encoding HIV-1 O RT p51 
gene was amplified using HIVRTO-HISF and HIVRTOp51-B, and the 1,706-bp DNA 
fragment encoding HIV-1 O RT p66 was amplified using HIVRTO-F and 
HIVRTOp66-B, both from the artificially synthesized HIV-1 O RT gene (Fig. S1B). The 
nucleotide sequences of the primers are shown in Table S1. These amplified DNAs were 
digested with NdeI and EcoRI, and inserted in pET-22b(+) to produce pET-MRTHis, 
pET-HisHIVMp51, pET-HIVMp66, pET-HisHIVOp51, and pET-HIVOp66 (Fig. 1). 
 
Expression and Purification of MMLV RT  
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BL21(DE3) [F-, ompT, hsdSB (rB -mB -) gal dcm (DE3)] cells were transformed with 
pET-HisMRT. The overnight culture of the transformants (8 mL) was added to 800 mL 
of L broth and incubated with shaking at 37ºC. When OD660 reached 0.6–0.8, 0.8 mL of 
0.5 M IPTG was added and growth was continued at 30ºC for 4 h. After centrifugation 
at 10,000 × g for 10 min, the cells were harvested, suspended with 20 mL of 10 mM 
Tris-HCl, 0.4% v/v Triton X-100, 10% v/v glycerol, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), pH 7.5 and disrupted by sonication. After centrifugation at 15,000 × g 
for 20 min, the supernatant was collected, to which solid (NH4)2SO4 was added to a 
final concentration of 40% saturation. After centrifugation at 20,000 × g for 20 min, the 
pellet was collected and dissolved in 6 mL of 0.02 M potassium phosphate, 2.0 mM 
dithiothreitol (DTT), 10% glycerol, pH 7.2 (0.02 M PDG) and dialyzed against the same 
buffer. The dialyzed solution was diluted to 60 mL with 2.0 mM DTT, 10% glycerol, pH 
7.2 (DG) and applied to a column [25 mm (inner diameter) × 120 mm] packed with 
Toyopearl DEAE-650M gel (Tosoh, Tokyo, Japan) equilibrated with 0.02 M PDG. The 
bound RT was eluted with 0.3 M potassium phosphate, 2.0 mM DTT, 10% glycerol, pH 
7.2 (0.3 M PDG). The eluate (10–15 mL) was diluted to 100 mL with 0.02 M PDG 
containing 20 mM imidazole and applied to the column packed with a Ni
2+
-sepharose 
(HisTrap HP 1 mL, GE Healthcare, Buckinghamshire, UK) equilibrated with 0.02 M 
PDG containing 20 mM imidazole. The bound RT was eluted with 0.02 M PDG 
containing 500 mM imidazole. The eluate was dialyzed against 20 mM potassium 
phosphate, 2.0 mM DTT, 50% glycerol, pH 7.2, and stored at -80°C. 
 
Expression and Purification of HIV-1 M RT and HIV-1 O RT 
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BL21(DE3) cells were transformed with pET-HisHIVMp51, pET-HIVMp66, 
pET-HisHIVOp51, or pET-HIVOp66, cultured, harvested, and suspended by the same 
method used for MMLV RT. For the production of HIV-1 M RT, the suspension 
containing the N-terminally (His)6-tagged HIV-1 M p51 and that containing the 
untagged HIV-1 M p66 were mixed. For the production of HIV-1 O RT, the suspension 
containing the N-terminally (His)6-tagged HIV-1 O p51 and that containing the 
untagged HIV-1 O p66 were mixed. HIV-1 M RT and HIV-1 O RT were purified and 
stored by the same methods used for MMLV RT.   
  
Measurement of RT activity to Incorporate dTTP into poly(rA)-p(dT)15   
 
The activity to incorporate dTTP into poly(rA)-p(dT)15 was measured as described 
previously [16]. Briefly, the reaction was carried out in 25 mM Tris-HCl (pH 8.3), 50 
mM KCl, 2.0 mM DTT, 5.0 mM MgCl2, 25 M poly(rA)-p(dT)15 (this concentration 
expressed as that of p(dT)15), 0.2 mM [
3
H]dTTP, and active fractions or purified 
preparations of RT at 37ºC. An aliquot (20 L) was taken from the reaction mixture at a 
predetermined time and immediately spotted onto the glass filter GF/C 2.5 cm 
(Whatman, Middlesex, UK). The amounts of [
3
H]dTTP incorporated was counted, and 
the initial reaction rate was determined.  
 
Measurement of RT Activity for cDNA Synthesis 
 
The activity for cDNA synthesis was measured as described previously [14]. Briefly, the 
reaction (20 L) was carried out in 25 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.0 mM 
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DTT, 0.1 mM dNTP, 0.5 M DNA primer (R12), 0.8 pg/L (corresponding to 2 pM) 
standard RNA, 0.05 g/L E. coli RNA, and various concentrations (0.1–1000 nM) of 
RT at 46ºC for 30 min and stopped by heating at 95ºC for 5 min. The PCR reaction (30 
L) was then carried out in 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 0.5 
M (each) DNA primers (F5 and RV), 0.1 mM dNTP, 10% v/v product of the reverse 
transcriptase reaction, and 0.05 U/l Taq polymerase. The cycling parameters were 95ºC 
for 30 s, followed by 30 cycles at 95ºC for 30 s, 55ºC for 30 s, and 72ºC for 60 s. The 
amplified products were separated on 1.0% agarose gels and stained with ethidium 
bromide (1 g/mL).  
 
Analysis of Irreversible Thermal Inactivation of RT 
 
Irreversible thermal inactivation of RT was analyzed as described previously [16]. 
Briefly, the thermal inactivation was carried out in 10 mM potassium phosphate (pH 
7.6), 2.0 mM DTT, 0.2% v/v Triton X-100, 10% glycerol, 28 M poly(rA)-p(dT)15 and 
20 nM MMLV RT, 500 nM HIV-1 M RT, or 200 nM HIV-1 O RT at a range of 
temperatures from 42 to 50ºC for 10 min followed by incubation on ice for 30–60 min. 
The remaining RT activity to incorporate dTTP into poly(rA)-p(dT)15 was determined at 






Production of Recombinant MMLV RT, HIV-1 M RT, and HIV-1 O RT 
 
To achieve a high-level production, we selected the C-terminus for MMLV RT and the 
N-terminus for HIV-1 M RT and HIV-1 O RT as the (His)6 binding site and 30°C for all 
RTs as the E. coli culture temperature after IPTG induction. Figure 1 shows five 
expression plasmids, pET-MRTHis for C-terminally (His)6-tagged MMLV RT, 
pET-HIVMp66 for untagged HIV-1 M p66, pET-HisHIVMp51 for N-terminally 
(His)6-tagged HIV-1 M p51, pET-HIVOp66 for untagged HIV-1 O p66, and 
pET-HisHIVOp51 for N-terminally (His)6-tagged HIV-1 O p51.  
Purification of MMLV RT was carried out from the E. coli cells containing the 
C-terminally (His)6-tagged MMLV RT. Purification of HIV-1 M RT and HIV-1 O RT 
was carried out from the mixture of the cells containing the untagged p66 and those 
containing the N-terminally (His)6-tagged p51. Ammonium sulfate fractionation was 
used as the first step, ion-exchange column chromatography as the second step, and Ni
2+ 
affinity column chromatography as the third step. The active fraction at the third step 
was dialyzed against the solution containing 50% glycerol. Figure 2 shows the results of 
SDS-PAGE analysis of the active fractions at each purification stage and the purified 
enzyme preparations. MMLV RT yielded a single band with a molecular mass of 75 
kDa, and HIV-1 M RT and HIV-1 O RT yielded two bands with molecular masses of 51 
and 66 kDa. Representative purification is shown in Table S2.  
 
Activities of Recombinant MMLV RT, HIV-1 M RT, and HIV-1 O RT 
 
Figure 3 shows the results of steady-state kinetic analysis of RT in the incorporation of 
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dTTP into poly(rA)-p(dT)15 (T/P). The dependences of the initial reaction rate (vo) on 
dTTP (Fig. 3A) and T/P (Fig. 3B) concentrations exhibited the Michaelis-Menten curves. 
The Km,dTTP, Km,T/P, and kcat values are summarized in Table 1. The Km,dTTP and Km,T/P 
values of the HIV-1 M RT and HIV-1 O RT were in the range of 8–25% of those of 
MMLV RT, suggesting that HIV-1 RT has higher affinity for dTTP and T/P than MMLV 
RT. The kcat values of HIV-1 M RT and HIV-1 O RT were 1.2 and 3.8% of that of 
MMLV RT, respectively. Consequently, the kcat/Km values of HIV-1 M RT and HIV-1 O 
RT were in the range of 5–32% of those of MMLV RT.  
Figure 4 shows cDNA synthesis activities of RT. The reaction was carried out at 
46ºC for 30 min with varying enzyme concentrations of 0–1,000 nM, followed by PCR 
of the cDNA synthesis reaction products and agarose gel electrophoresis of the PCR 
products. In all RTs, the amplified product with the expected size of 601 bp was 
detected for the enzyme concentrations of 0.1–10 nM, but not for those of 50–1,000 nM. 
This indicates that all RTs have similar cDNA synthesis activities.  
Formamide and dimethyl sulfoxide (DMSO) are frequently used for the polymerase 
chain reaction (PCR) with a G+C-rich DNA to improve specificity [18–20]. Figure 5 
shows the activities of RT to incorporate dTTP into T/P in the presence of various 
concentrations (0–30% v/v) of formamide or DMSO at 42ºC. The relative activity was 
defined as the ratio of the initial reaction rate in the presence of the indicated organic 
solvent to that in its absence (61.8 nM s
-1
 for MMLV RT, 34.0 nM s
-1
 for HIV-1 M RT, 
and 33.9 nM s
-1
 for HIV-1 O RT). Formamide and DMSO inhibited the activity in a 
dose-dependent manner. The HIV-1 M RT and HIV-1 O RT activities were slightly 
enhanced in the presence of 4–18% formamide, and the MMLV RT activity was slightly 
enhanced in the presence of 2–16% DMSO. The concentrations required to decrease the 
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activities of MMLV RT, HIV-1 M RT, and HIV-1 O RT to 50% of the maximum activity 
(IC50) of formamide were 8, 22, and 22%, respectively, and those of DMSO were 21, 16, 
and 16%, respectively. This indicates that Formamide affects MMLV RT more potently 
than HIV-1 M RT and HIV-1 O RT, while DMSO affects HIV-1 M RT and HIV-1 O RT 
more potently than MMLV RT. 
 
Stabilities of Recombinant MMLV RT, HIV-1 M RT, and HIV-1 O RT 
 
Figure 6 shows the remaining activities of RT to incorporate dTTP into T/P after 
thermal treatment at 42–50ºC for 10 min. The relative activities, which were defined as 
the ratio of the initial reaction rate with incubation at the indicated temperature for 10 
min to that without incubation, of all RTs decreased with increasing temperature. The 
relative activities of HIV-1 O RT were higher than those of MMLV RT and HIV-1 M 
RT at all temperatures examined. The temperatures reducing initial activity by 50% in 
10-min incubation, T50, of MMLV RT, HIV-1 M RT, and HIV-1 O RT were estimated 
about 44, 42, and 46ºC. This suggests that the thermal stability of HIV-1 O RT is 
slightly higher than those of MMLV RT and HIV-1 M RT.  




In the dTTP incorporation reaction, the Km and kcat values of HIV-1 M RT and 
HIV-1 O RT were lower than those of MMLV RT (Fig. 3, Table 1). This finding 
suggests that HIV-1 RT has higher substrate affinity but lower enzyme processivity than 
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MMLV RT. All three RTs exhibited similar cDNA synthesis activities (Fig. 4). In the 
dTTP incorporation reaction, the initial substrate concentrations (0.2 mM dTTP and 25 
M T/P) were higher than the enzyme concentration (2–20 nM), whereas in the cDNA 
synthesis reaction, the initial substrate concentration (2 pM target RNA) was lower than 
the enzyme concentration (0.1–10 nM). In most cDNA synthesis reactions, the initial 
concentration of target RNA is considerably lower than that of the RT. Thus, HIV-1 RT 
has an advantage over MMLV RT because it has a higher substrate affinity. HIV-1 can 
infect both dividing and non-dividing cells, whereas, MMLV can infect only dividing 
cells. The clear difference in kinetic parameters can be explained by the fact that RT has 
evolved to facilitate viral replication under specific cellular environments with different 
substrate concentrations. Such differences for recombinant RTs were reported in feline 
leukemia virus and feline immunodeficiency virus [21].   
All RTs exhibited similar cDNA synthesis defects at high enzyme concentrations 
(50–1,000 nM). Similar result was obtained for the MMLV RT variant D524A, wherein 
the catalytically important residue for RNase H activity, Asp524, was substituted with 
Ala to abolish RNase H activity and increase stability (data not shown). We speculate 
that this defect is due to increased nonspecific binding of RT to T/P rather than 
enhanced RNA cleavage. 
We previously reported that 6–8% formamide and 12% DMSO improved the 
efficiency of MMLV RT-catalyzed cDNA synthesis at low temperatures (25–34ºC) [20]. 
We presume this effect is due to the increase in primer specificity caused by reducing 
secondary RNA structure and nonspecific binding of the primer, as previously reported 
[18, 19]. Formamide is also used in RNA isolation [22] and storage [23]. In this study, 
compared with MMLV RT, HIV-1 M RT and HIV-1 O RT were less susceptible to 
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formamide but more susceptible to DMSO (Fig. 5), suggesting that formamide more 
effectively enhances cDNA synthesis by HIV-1 RT. The mechanism underlying the 
difference in the inhibitory effects of DMSO and formamide on MMLV RT and HIV-1 
RT activity is unknown.  
HIV-1 O RT exhibited slightly higher thermal stability than MMLV RT and HIV-1 
M RT (Fig. 6), which is in agreement with the previous report [10]. The reason for the 
difference in stability of HIV-1 M RT and HIV-1 O RT is unknown. We generated a 
highly thermostable MMLV RT variant, E286R/E302K/L435R/D524A, by introducing 
positive charges into the positions that have been implicated in the interaction with T/P 
by site-directed mutagenesis [24]. We also generated a highly stable AMV RT  subunit 
variant V238R/L388R/D450A by introducing the triple mutation 
(Val238→Arg/Leu388→Arg/Asp450→Ala) corresponding to the mutation introduced 
into MMLV RT (Glu286→Arg/Leu435→Arg/Asp524→Ala) [25]. Same strategy might 
be applicable to stabilize HIV-1 M RT and HIV-1 O RT. 
In conclusion, both HIV-1 M RT and HIV-1 O RT exhibited high affinity for 
DNA-primed RNA template and low susceptibility to formamide. Our results suggest 
that the use of HIV-1 RT in cDNA synthesis is attractive for detection of a small 
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Fig. 1 Expression plasmids. The structures of pET-MRTHis, pET-HIVMp66, 
pET-HisHIVMp51, pET-HIVOp66, and pET-HisHIVOp51 are shown. The asterisk 
indicates the termination codon   
 
Fig. 2 SDS-PAGE analysis. CBB-stained 10% SDS-polyacryl amide gel is shown. 
(A-C) Active fractions of each purification stage for MMLV RT (A), HIV-1 M RT (B), 
and HIV-1 O RT (C). Lanes: marker proteins (lane 1), soluble fractions of the total 
extracts (lane 2), the centrifuged pellets after fractionation by ammonium sulfate at 40% 
saturation (lane 3), active fractions of ion-exchange chromatography (lane 4) and Ni
2+
 
affinity chromatography before (lane 5) and after (lane 6) dialysis 
  
Fig. 3 Dependence on substrate concentration of the initial reaction rate (vo) in the 
incorporation of dTTP into poly(rA)-p(dT)15. (A) Dependence on dTTP concentration. 
(B) Dependence on poly(rA)-p(dT)15 concentration. The initial concentrations of 
MMLV RT, HIV-1 M RT, and HIV-1 O RT were 2, 50, and 20 nM, respectively. The 
initial concentration of poly(rA)-p(dT)15 was 25 M (A), and that of dTTP was 200 M 
(B). Solid lines represent the best fit of the Michaelis-Menten equation with the 
non-linear least squares method. Symbols for the enzymes: MMLV RT (open circle), 
HIV-1 M RT (open triangle), and HIV-1 O RT (open square) 
 
Fig. 4 Dependence on enzyme concentration of RT-catalyzed cDNA synthesis. (A) 
MMLV RT. (B) HIV-1 M RT. (C) HIV-1 O RT. cDNA synthesis was carried out with 0 
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(lane 2), 0.1 (lane 3), 0.5 (lane 4), 1.0 (lane 5), 5.0 (lane 6), 10 (lane 7), 50 (lane 8), 100 
(lane 9), 500 (lane 10), 1,000 (lane 11) nM MMLV RT (A), HIV-1 M RT (B), and HIV-1 
O RT (C) at 46°C. Then, PCR was carried out. Marker DNAs (lane 1) and the amplified 
products (lanes 2-11) were separated on 1.0% agarose gels and stained with ethidium 
bromide. The arrow indicates the expected size (601 bp) of the amplified products  
 
Fig. 5 Dependence on organic solvent concentration of RT-catalyzed incorporation of 
dTTP into poly(rA)-p(dT)15. The reaction was carried out at 42°C with the initial 
enzyme concentrations of 2 nM for MMLV RT, 50 nM for HIV-1 M RT, and 20 nM for 
HIV-1 O RT and the initial poly(rA)-p(dT)15 and [
3
H]dTTP concentrations of 25 M 
and 0.2 mM, respectively, in the presence of 0–30% formamide (A) or DMSO (B). 
Symbols for the enzymes: MMLV RT (open circle), HIV-1 M RT (open triangle), and 
HIV-1 O RT (open square) 
 
Fig. 6 Irreversible thermal inactivation of RT. MMLV RT (20 nM), HIV-1 M RT (500 
nM), and HIV-1 O RT (200 nM) were incubated at 42–50°C in the presence or absence 
of poly(rA)-p(dT)15 (T/P) (28 M) for 10 min. Then, the reaction to incorporate dTTP 
into poly(rA)-p(dT)15 was carried out at 37°C with the initial enzyme concentrations of 




MMLV RT  




pET-HisHIVOp51 (7,153 bp) 
pET-MRTHis (His)6
ATGACATGGCTGTCTGATTTTCCTCAG
M  T  W  L  S  D  F  P  Q   
CCAGACACCTCTACCCTCCTCCACCACCACCATCACCACTAG
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Table 1  
Kinetic parameters of RT in the to incorporation of dTTP into poly(rA)-p(dT)15 (T/P) at 
37ºC. 
 
RT      Km, dTTP (M)         Km,T/P (M)    kcat (s
-1
)         
MMLV RT   250 ± 60 (1.0)      5.6 ± 0.8 (1.0)      29 ± 6 (1.0) 
HIV-1 M RT    20 ± 2 (0.080)     1.4 ± 0.2 (0.25)      0.35 ± 0.02 (0.012) 
HIV-1 O RT    30 ± 4 (0.12)    1.3 ± 0.4 (0.23)       1.1 ± 0.1 (0.038) 
 
Average of triplicate determinations with SD value is shown. Numbers in parentheses 
indicate values relative to MMLV RT.  
1     CCGATTAGCCCGATTGAAACTGTGCCCGTTAAACTGAAACCAGGTATGGATGGACCGAAAGTAAAACAATGGCCACTGACAGAAGAAAAG 
1     P  I  S  P  I  E  T  V  P  V  K  L  K  P  G  M  D  G  P  K  V  K  Q  W  P  L  T  E  E  K 
 
  91     ATTAAAGCACTGGTTGAAATTTGCACCGAAATGGAAAAAGAAGGCAAAATCTCTAAAATTGGGCCCGAGAACCCGTATAACACCCCGCTG 
31     I  K  A  L  V  E  I  C  T  E  M  E  K  E  G  K  I  S  K  I  G  P  E  N  P  Y  N  T  P  V 
 
181     TTTGCAATTAAAAAAAAAGATTCTACAAAGTGGCGTAAATTGGTAGATTTCCGCGAGCTTAATAAACGCACTCAAGATTTCTGGGAAGTT 
61     F  A  I  K  K  K  D  S  T  K  W  R  K  L  V  D  F  R  E  L  N  K  R  T  Q  D  F  W  E  V 
 
 271     CAACTTGGGATTCCTCACCCCGCCGGTCTGAAAAAGAAAAAATCAGTGACTGTTTTGGATGTAGGAGATGCATATTTTAGCGTCCCCTTG 
91     Q  L  G  I  P  H  P  A  G  L  K  K  K  K  S  V  T  V  L  D  V  G  D  A  Y  F  S  V  P  L 
 
361     GATTTCGATTTTCGTAAATATACCGCATTCACTATCCCGTCTATTAACAATGAAACACCAGGCATTCGTTACCAATATAACGTACTTCCT 
121     D  F  D  F  R  K  Y  T  A  F  T  I  P  S  I  N  N  E  T  P  G  I  R  Y  Q  Y  N  V  L  P 
 
451     CAAGGTTGGAAAGGCTCTCCCGCCATTTTTCAGTCGAGTATGACTAAAATCTTGGAACCTTTCCGCAAACAAAATCCGGACATTGTTATC 
151     Q  G  W  K  G  S  P  A  I  F  Q  S  S  M  T  K  I  L  E  P  F  R  K  Q  N  P  D  I  V  I 
 
541     TACCAGTACATGGATGATCTGTATGTTGGATCCGACCTGGAAATCGGACAACATCGCACAAAAATCGAAGAGCTGCGTCAACACCTTCTG 
181     Y  Q  Y  M  D  D  L  Y  V  G  S  D  L  E  I  G  Q  H  R  T  K  I  E  E  L  R  Q  H  L  L 
 
601     CGCTGGGGCTTGACTACACCTGACAAAAAACATCAAAAAGAACCACCGTTCCTGTGGATGGGTTATGAATTGCACCCTGACAAATGGACC 
201     R  W  G  L  T  T  P  D  K  K  H  Q  K  E  P  P  F  L  W  M  G  Y  E  L  H  P  D  K  W  T 
                          
721     GTTCAACCTATCGTCCTGCCCGAAAAAGACAGCTGGACGGTTAATGACATTCAAAAGTTGGTAGGCAAGTTAAATTGGGCATCTCAGATT 
241     V  Q  P  I  V  L  P  E  K  D  S  W  T  V  N  D  I  Q  K  L  V  G  K  L  N  W  A  S  Q  I 
 
811     TACCCGGGCATTAAAGTGCGCCAACTTTGTAAACTGCTGCGCGGCACCAAGGCTCTGACCGAAGTCATCCCTCTGACCGAAGAAGCTGAA 
271     Y  P  G  I  K  V  R  Q  L  C  K  L  L  R  G  T  K  A  L  T  E  V  I  P  L  T  E  E  A  E 
 
901     CTGGAACTTGCAGAGAACCGCGAAATTCTGAAAGAACCCGTCCATGGAGTGTATTATGACCCAAGTAAAGATTTGATTGCCGAAATTCAA 
301     L  E  L  A  E  N  R  E  I  L  K  E  P  V  H  G  V  Y  Y  D  P  S  K  D  L  I  A  E  I  Q 
 
991     AAACAAGGACAAGGCCAATGGACCTATCAGATTTATCAAGAACCTTTTAAAAACTTAAAAACTGGAAAATATGCACGCATGCGCGGTGCG 
331     K  Q  G  Q  G  Q  W  T  Y  Q  I  Y  Q  E  P  F  K  N  L  K  T  G  K  Y  A  R  M  R  G  A 
 
1081     CATACAAACGATGTTAAACAGCTGACAGAAGCCGTACAAAAAATTACAACAGAATCCATTGTAATCTGGGGAAAAACACCGAAATTTAAA 
361     H  T  N  D  V  K  Q  L  T  E  A  V  Q  K  I  T  T  E  S  I  V  I  W  G  K  T  P  K  F  K 
 
1171     TTACCGATTCAAAAAGAGACGTGGGAAACGTGGTGGACCGAATACTGGCAGGCAACCTGGATTCCGGAATGGGAATTTGTAAACACCCCA 
391     L  P  I  Q  K  E  T  W  E  T  W  W  T  E  Y  W  Q  A  T  W  I  P  E  W  E  F  V  N  T  P 
 
1261     CCATTAGTTAAACTCTGGTATCAACTCGAAAAAGAACCGATTGTAGGGGCAGAAACTTTTTATGTGGACGGAGCTGCGAATCGCGAAACG 
421     P  L  V  K  L  W  Y  Q  L  E  K  E  P  I  V  G  A  E  T  F  Y  V  D  G  A  A  N  R  E  T   
       
1351     AAATTAGGTAAAGCTGGATATGTGACGAATCGCGGGCGCCAAAAAGTAGTAACCCTCACCGATACCACTAATCAAAAAACCGAACTCCAA 
451     K  L  G  K  A  G  Y  V  T  N  R  G  R  Q  K  V  V  T  L  T  D  T  T  N  Q  K  T  E  L  Q 
 
1441     GCAATTTACCTCGCCCTGCAAGATTCAGGCTTAGAAGTTAACATTGTCACTGATAGCCAATACGCCCTTGGTATTATTCAAGCACAGCCG 
481     A  I  Y  L  A  L  Q  D  S  G  L  E  V  N  I  V  T  D  S  Q  Y  A  L  G  I  I  Q  A  Q  P    
 
1531     GATCAAAGCGAATCAGAATTAGTCAATCAGATTATTGAACAATTAATTAAAAAAGAGAAAGTATATTTAGCCTGGGTACCAGCCCATAAA 
511     D  Q  S  E  S  E  L  V  N  Q  I  I  E  Q  L  I  K  K  E  K  V  Y  L  A  W  V  P  A  H  K 
 
1621     AAAGGAATTGGTGGCAACGAACAGGTAGACAAACTGGTATCTGCAGGTATTCGTAAAGTTTTATAA 
541     K  G  I  G  G  N  E  Q  V  D  K  L  V  S  A  G  I  R  K  V  L  *    
Fig. S1  Nucleotide sequences of artificially synthesized HIV-1 M RT 
DNA. The amino acid sequences is also shown
1     CCGATCTCGCCGATTGCTCCGGTGCCGGTGAAACTGAAACCGGGTATGGATGGTCCGAAAGTGAAACAATGGCCGCTGTCTCGTGAAAAA
   1     P  I  S  P  I  A  P  V  P  V  K  L  K  P  G  M  D  G  P  K  V  K  Q  W  P  L  S  R  E  K 
 
  91     ATTGAAGCACTGACCGCTATCTGCCAGGAAATGGAACAAGAAGGCAAAATTTCACGTATCGGTCCGGAAAACCCGTATAATACGCCGATT
   31     I  E  A  L  T  A  I  C  Q  E  M  E  Q  E  G  K  I  S  R  I  G  P  E  N  P  Y  N  T  P  I 
 
 181     TTTGCCATTAAGAAAAAAGATTCGACCAAATGGCGCAAACTGGTGGACTTTCGTGAACTGAACAAACGCACGCAGGATTTCTGGGAAGTT
   61     F  A  I  K  K  K  D  S  T  K  W  R  K  L  V  D  F  R  E  L  N  K  R  T  Q  D  F  W  E  V 
 
 271     CAACTGGGCATTCCGCATCCGGGCGGTCTGAAACAGCGTCAATCAGTTACCGTCCTGGATGTGGGTGACGCCTATTTCTCGTGTCCGCTG
   91     Q  L  G  I  P  H  P  G  G  L  K  Q  R  Q  S  V  T  V  L  D  V  G  D  A  Y  F  S  C  P  L 
 
 361     GATCCGGACTTTCGTAAATACACCGCATTCACGATCCCGAGCGTTAACAATGAAACCCCGGGCGTGCGCTATCAGTACAACGTTCTGCCG
  121     D  P  D  F  R  K  Y  T  A  F  T  I  P  S  V  N  N  E  T  P  G  V  R  Y  Q  Y  N  V  L  P 
 
 451     CAAGGCTGGAAAGGTTCTCCGGCTATTTTTCAGAGCTCTATGACCAAAATCCTGGATCCGTTCCGTAAAAGTAATCCGGAAGTGGAAATT
  151     Q  G  W  K  G  S  P  A  I  F  Q  S  S  M  T  K  I  L  D  P  F  R  K  S  N  P  E  V  E  I 
 
 541     TATCAGTACATCGATGACCTGTATGTTGGTTCCGATCTGCCGCTGGCAGAACATCGTAAACGCGTGGAACTGCTGCGCGAACACCTGTAC
  181     Y  Q  Y  I  D  D  L  Y  V  G  S  D  L  P  L  A  E  H  R  K  R  V  E  L  L  R  E  H  L  Y 
 
 631     CAGTGGGGCTTTACCACGCCGGATAAAAAACATCAGAAAGAACCGCCGTTCCTGTGGATGGGTTATGAACTGCACCCGGACAAATGGACG
  211     Q  W  G  F  T  T  P  D  K  K  H  Q  K  E  P  P  F  L  W  M  G  Y  E  L  H  P  D  K  W  T 
 
 721     GTTCAGCCGATTCAACTGCCGGATAAAGAAGTGTGGACCGTTAACGACATCCAGAAACTGGTCGGCAAACTGAATTGGGCCAGCCAGATT
  241     V  Q  P  I  Q  L  P  D  K  E  V  W  T  V  N  D  I  Q  K  L  V  G  K  L  N  W  A  S  Q  I 
 
 811     TACCAAGGTATCCGTGTGAAAGAACTGTGCAAACTGATTCGCGGCACGAAAAGCCTGACCGAAGTGGTTCCGCTGTCTAAAGAAGCAGAA
  271     Y  Q  G  I  R  V  K  E  L  C  K  L  I  R  G  T  K  S  L  T  E  V  V  P  L  S  K  E  A  E 
 
 901     CTGGAACTGGAAGAAAACCGCGAAAAACTGAAAGAACCGGTCCATGGTGTGTATTACCAGCCGGATAAAGACCTGTGGGTTAGCATTCAG
  301     L  E  L  E  E  N  R  E  K  L  K  E  P  V  H  G  V  Y  Y  Q  P  D  K  D  L  W  V  S  I  Q 
 
 991     AAACATGGCGAAGGTCAATGGACCTATCAGGTCTACCAAGATGAACACAAAAACCTGAAAACGGGCAAATACGCGCGTCAGAAAGCCAGC
  331     K  H  G  E  G  Q  W  T  Y  Q  V  Y  Q  D  E  H  K  N  L  K  T  G  K  Y  A  R  Q  K  A  S 
 
1081     CACACCAATGACATCCGCCAGCTGGCTGAAGTCGTGCAGAAAGTCTCTCAAGAAGCGATTGTGATCTGGGGTAAACTGCCGAAATTTCGT
  361     H  T  N  D  I  R  Q  L  A  E  V  V  Q  K  V  S  Q  E  A  I  V  I  W  G  K  L  P  K  F  R 
 
1171     CTGCCGGTGACCCGCGAAACGTGGGAAACCTGGTGGGCCGAATATTGGCAGGCAACGTGGATTCCGGAATGGGAATTTGTTAGTACCCCG
  391     L  P  V  T  R  E  T  W  E  T  W  W  A  E  Y  W  Q  A  T  W  I  P  E  W  E  F  V  S  T  P 
            
1261     CCGCTGATTAAACTGTGGTATCAGCTGGAAACGGAACCGATCGTTGGCGCTGAAACCTTCTACGTCGATGGTGCGGCCAACCGTAATACG
  421     P  L  I  K  L  W  Y  Q  L  E  T  E  P  I  V  G  A  E  T  F  Y  V  D  G  A  A  N  R  N  T 
        
1351     AAACTGGGCAAAGCGGGTTATGTGACCGAACAGGGCAAACAAAACATTATCAAACTGGAAGAAACCACGAATCAGAAAGCAGAACTGATG
  451     K  L  G  K  A  G  Y  V  T  E  Q  G  K  Q  N  I  I  K  L  E  E  T  T  N  Q  K  A  E  L  M 
 
1441     GCTGTTCTGATTGCGCTGCAGGATAGTAAAGAACAAGTTAATATCGTCACGGACTCCCAGTACGTCCTGGGTATTATCAGTTCCCAGCCG
  481     A  V  L  I  A  L  Q  D  S  K  E  Q  V  N  I  V  T  D  S  Q  Y  V  L  G  I  I  S  S  Q  P 
 
1531    ACCCAATCAGATTCGCCGATTGTCCAGCAAATTATCGAAGAACTGACCAAAAAAGAACGCGTGTATCTGACCTGGGTTCCGGCACACAAA
  511    T  Q  S  D  S  P  I  V  Q  Q  I  I  E  E  L  T  K  K  E  R  V  Y  L  T  W  V  P  A  H  K 
 
1621    AAAGGCATCGGCGGTAACGAAAAAATTGATAAACTGGTTTCTAAAGACATTCGTCGTGTTTTATAA 
  541    K  G  I  G  G  N  E  K  I  D  K  L  V  S  K  D  I  R  R  V  L  * 
Fig. S2  Nucleotide sequences of artificially synthesized HIV-1 M RT 
DNA. The amino acid sequences is also shown
 1 
Table S1  
Primers.  
 
















 TTAGAAACCAGTTTATCAATTTTTTCG-3’       
The mismatched nucleotides with the sequence of the MMLV RT, HIV-1 M RT, or 
HIV-1 O RT gene are underlined. 
 2 
Table S2  
Representative purification of RT.      
                                   
              Volume   Activity   Recovery   Protein  Specific activity  Purification 
Stage                   (mL)    (unitsa)      (%)      (mg)     (units/mg)      (fold) 
i) MMLV RT 
(NH4)2SO4 fractionation  6.0    928,000    100       21 44,000       1.0 
DEAE Toyopearl    16 553,000     60       13 43,000       1.0  
Ni2+ Sepharose             2.5 629,000     68        4.3     150,000       3.4 
Purified enzyme   0.7    372,000     40        2.0     190,000       4.3 
ii) HIV-1 group M RT 
(NH4)2SO4 fractionation  8.0      6,310    100       24   260       1.0 
DEAE Toyopearl    16   5,070     80        7.5   680       2.6  
Ni2+ Sepharose             2.5   2,080     33        1.3   1,500       5.8 
Purified enzyme   0.7      1,760     28        0.9   1,900       7.3 
iii) HIV-1 group O RT 
(NH4)2SO4 fractionation 12      16,800    100       52   320       1.0 
DEAE Toyopearl    28  20,400    120       21   970       3.0  
Ni2+ Sepharose             2.5   5,190     31        1.3  4,000      13 
Purified enzyme   0.7      3,910     23        0.8  5,000      16 
 
a
One unit of RT is defined as the amount which incorporates 1 nmol of dTTP into 
poly(rA)-p(dT)15 in 10 min at 37ºC. 
  
 
